| Â | ADMA | SDMA | ADMA:SDMA |
|---|
Factor | Main Eff. | Inflam. | Int. | Main Eff. | Inflam. | Int. | Main Eff. | Inflam. | Int. |
|---|
Log2ACh | 0.390 | 0.954 | 0.636 |
0.008
|
0.030
|
0.014
|
0.007
| 0.093 |
0.027
|
Log2SNP | 0.702 | 0.989 | 0.824 | 0.074 | 0.056 |
0.042
| 0.100 | 0.151 | 0.087 |
Log2FMD | 0.363 | 0.767 | 0.677 | 0.420 | 0.097 | 0.092 | 0.174 | 0.138 | 0.110 |
Log2GTN | 0.754 | 0.702 | 0.823 | 0.799 | 0.812 | 0.868 | 0.959 | 0.607 | 0.737 |
Log2cIMT | 0.217 | 0.323 | 0.051 | 0.550 | 0.265 | 0.562 | 0.607 | 0.953 | 0.259 |
Log2SEVR | 0.876 | 0.727 | 0.706 |
0.006
|
0.049
| 0.052 | 0.058 | 0.252 | 0.268 |
AIx (HR 75) | 0.204 | 0.367 | 0.246 | 0.205 | 0.221 | 0.127 | 0.050 | 0.097 |
0.036
|
-
p values from general linear models, with three terms included in each model: Main Eff. – the main effect of the factor being considered, Inflam. – a binary variable, stating whether a patient had high levels of inflammation (ESR > 25 and CRP > 5), Int. – an interaction term between Main Eff. and Inflam., testing whether the relationship between the factor and outcome differs by the degree of inflammation. Bold p values are significant at p < 0.05
-
ADMA asymmetric dimethylarginine, SDMA symmetric dimethylarginine, ACh acetylcholine, SNP sodium nitroprusside, FMD flow-mediated dilatation, GTN glyceryl-trinitrate mediated dilatation, cIMT intima media thickness, SEVR subendocardial viability ratio, AIx augmentation index, HR heart rate
